Relay Therapeutics announced its Q1 2026 financial results and key updates, including FDA granting Breakthrough Therapy designation to its drug zovegalisib for PIK3CA-mutant advanced breast cancer. The company reported promising clinical data showing an 11.1-month median progression-free survival in heavily pre-treated breast cancer patients and plans to start a Phase 3 frontline trial in early 2027. Relay also initiated a Phase 1/2 trial for RLY-8161 targeting NRAS-mutant tumors and expects initial vascular anomalies data in May 2026. With $642 million in cash, the company is well-funded to continue its clinical programs through 2029.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
A large Chainlink whale accumulated 1.58 million LINK tokens worth about $13.3 million by withdrawing from Binance, reducing exchange supply and signaling confidence. Despite this, LINK's price remained stable above the $8.18 support level without a ...
Pump.fun (PUMP) surged 11.60% to $0.002001, boosting its market cap to $794.91 million, driven by a community initiative attracting trader interest. Other notable gainers include Aave, Shiba Inu, Provenance Blockchain, and Pepe, all rising between 8....
Ares Capital (ARCC) is recommended as a buy due to its reliable 10.13% dividend yield and disciplined distribution coverage. Since 2022, ARCC's cumulative profits and realized gains have exceeded its distributions by $1.05 billion, showing strong fin...
